SCbio, a life sciences organization, announced March 27 it has named three Upstate professionals as leaders on its Fiduciary & Operations Board.
The appointed Upstate leaders include:
- Rymedi Founder & CEO David Stefanich, Greenville – board chair
- Christopher Hanson, partner with Nelson Mullins in Greenville – vice chair
- Matthew Cannon, dean for Edward Via College of Osteopathic Medicine-Carolinas in Spartanburg – secretary
Joining Stefanich, Hanson and Cannon in board leadership are:
- Nephron Pharmaceuticals CEO and Owner Lou Kennedy, Columbia – past chair
- Vikor Scientific COO Dan Nodes, Charleston – treasurer
SCbio’s Fiduciary & Operations Board also welcomed six officers, including:
- Greg Marshall of Charles River Labs
- Thornton Kirby of SC Hospital Association
- Cynthia Young of Clemson University College of Science
- S.C. Department of Commerce Deputy Secretary Ashely Teasdel
- Herbert Drayton of HI Mark Capital
- Scott Pancoast of Zylö Therapeutics
“In a state well-known for building BMWs, Boeing Dreamliners and Michelin tires, South Carolina’s life sciences story is booming as well, creating exciting opportunities to diversify and accelerate growth of our knowledge economy,” said SCbio President and CEO James Chappell.
The state’s life sciences industry encompasses more than 1,000 firms involved in the research, development and commercialization of innovative health care, medical devices, and industrial, environmental and agricultural biotechnology products.
